Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | DPP4 | P27487 | 3/20 | 0.44 |
| ▸ | RORC | P51449 | 1/20 | 0.43 |
| ▸ | STS | P08842 | 3/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.40 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.40 |
| ▸ | KAT5 | Q92993 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
| ▸ | IL1B | P01584 | 1/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25044113 | 0.84 | STS (0.46) | MEN1MAPK1KMT2ARORCSTS | |
| SCHEMBL528371 | 0.84 | DPP4 (0.49) | DPP4RORCSTSUSP30KAT6A | |
| SCHEMBL528557 | 0.81 | RORC (0.45) | DPP4RORCUSP30NAMPTGPR119 | |
| SCHEMBL148144 | 0.81 | RORC (0.49) | MEN1KMT2ADPP4RORCUSP30 | |
| SCHEMBL1725669 | 0.81 | RORC (0.49) | MEN1KMT2ADPP4RORCUSP30 | |
| SCHEMBL148143 | 0.81 | RORC (0.49) | MEN1KMT2ADPP4RORCUSP30 | |
| SCHEMBL148142 | 0.81 | RORC (0.49) | MEN1KMT2ADPP4RORCUSP30 | |
| SCHEMBL527646 | 0.81 | DPP4 (0.53) | MEN1KMT2ADPP4RORCSTS | |
| SCHEMBL31449915 | 0.81 | KMT2A (0.45) | MEN1MAPK1KMT2ADPP4RORC | |
| SCHEMBL31449797 | 0.81 | KMT2A (0.45) | MEN1MAPK1KMT2ADPP4RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10087166-B2 | Cyclic amine azaheterocyclic carboxamides | MERCK PATENT GMBH (DE) | 2018-10-02 | — | — | US | disclosed |
| US-20170129877-A1 | Cyclic Amine Azaheterocyclic Carboxamides | MERCK PATENT GMBH (DE) | 2017-05-11 | — | — | US | disclosed |
| US-9586938-B2 | Cyclic amine azaheterocyclic carboxamides | MERCK PATENT GMBH (DE) | 2017-03-07 | — | — | US | disclosed |
| US-20130217709-A1 | Cyclic Amine Azaheterocyclic Carboxamides | MERCK PATENT GMBH (DE) | 2013-08-22 | — | — | US | disclosed |
| EP-2598497-A1 | CYCLIC AMINE AZAHETEROCYCLIC CARBOXAMIDES | Merck Patent GmbH (DE) | 2013-06-05 | — | — | EP | disclosed |
| WO-2012016001-A1 | CYCLIC AMINE AZAHETEROCYCLIC CARBOXAMIDES | MERCK PATENT GMBH (DE) | 2012-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130217709-A1 | Cyclic Amine Azaheterocyclic Carboxamides | MKI67, AZI2, PCNA | MEN1 563/4885MAPK1 1284/4885KMT2A 105/4885 |
| US-20170129877-A1 | Cyclic Amine Azaheterocyclic Carboxamides | MKI67, AZI2, PCNA | MEN1 563/4885MAPK1 1284/4885KMT2A 105/4885 |
| US-10087166-B2 | Cyclic amine azaheterocyclic carboxamides | MKI67, AZI2, PCNA | MEN1 563/4885MAPK1 1284/4885KMT2A 105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.